Skip to main content
OpenTrials
Completed

NCT Number: NCT01141504

Effect of Oral Adenosine-triphosphate (ATP) on Human Muscle Performance

Adenosine-triphosphate (ATP) serves as the sole energy source for muscle contraction. Therefore human performance of brief maximal exercise is limited, in part, by the availability of ATP to the contracting muscle. Because muscle ATP storage is small (enough to sustain maximal exercise for less than 1 second), factors that enhance either storage or resynthesis of ATP may have a positive impact on repeated muscle contractions. The current study will test the hypothesis that increasing ATP availability to muscle via oral supplementation will improve performance of repeated high intensity exercise as measured by a) work performed in each of the three 50 contraction fatigue tests, b) sum of total work performed, and c) percentage decrement in total work from the first to third third 50 contraction test.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Healthy Subjects

Age range

20 year–30 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Iowa State University

Ames, Iowa, 50010, United States

About this study

To date we have studied 10 subjects who have followed through with all 3 of the original interventions (Placebo, 250 mg PeakATP/d and 400 mg PeakATP/d). Currently we have received approval and are expanding the study with 5 additional subjects who will receive the Placebo, 400 mg PeakATP/d and the 400 mg PealATP/d plus proprietary blend interventions.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • No major medical conditions;
  • Able to perform fatigue testing procedures;
  • Not currently taking prescription medications;
  • Not currently taking dietary supplements (a daily multi-vitamin not exceeding RDA is permitted)

Exclusion criteria

  • Major medical condition affecting metabolism or general function;
  • Not able to perform fatigue testing;
  • Taking prescription medications;
  • Taking a dietary supplement other than a multi-vitamin not exceeding RDA

Treatment and study plan

PeakATP 250

Dietary Supplement

The nutritional intervention provides for oral ingestion of 250 mg PeakATP per day

Placebo

Dietary Supplement

Placebo capsules that are comparable in size and color to the active comparator for blinding purposes

PeakATP 400

Dietary Supplement

The nutritional intervention provides for oral ingestion of 400 mg PeakATP per day

PeakATP 400 plus proprietary blend

Dietary Supplement

The nutritional intervention provides for oral ingestion of 400 mg PeakATP per day plus a proprietary blend of additional nutrients

Primary outcomes

  1. Work Performed

    Time frame: Measured after 15 days of intervention

    The work and total work performed in 3 exercise fatigue tests given after 15 days of nutritional intervention.

Secondary outcomes

  1. Decrease in work performed in each successive test

    Time frame: Measured after 15 days of intervention

    The decrease in total work performed in each of 3 successive fatigue tests will be measured and used as a measure of muscle fatigability after 15 days of nutritional intervention

Sponsors and collaborators

Lead sponsor

Metabolic Technologies Inc.

Industry

Collaborators

  • Iowa State University

Registry information

Official study title

Effect of Oral ATP on Human Muscle Performance

Important dates

Study start
2010
Primary completion
2011
Study completion
2011
First posted
Jun 10, 2010
Registry last updated
Jan 10, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.